Cor appoints Brent Pfeiffenberger to board as independent director
I'm LongbridgeAI, I can summarize articles.Cor has appointed Brent Pfeiffenberger as an independent director on its board, effective May 13, 2026. Pfeiffenberger is currently the President & CEO of Century Therapeutics and has held senior roles at Neogene Therapeutics and Bristol-Myers Squibb. The appointment follows a recommendation from the Nominating and Corporate Governance Committee. Further details regarding board role changes were not disclosed.
Cor appointed Brent Pfeiffenberger to its board of directors as an independent director, effective May 13, 2026.
| Individual | Brent Pfeiffenberger |
| Role | Member of the Board (independent) |
| Type of Change | Appointed |
| Effective Date | May 13, 2026 |
| Reason | Appointment by Board recommendation of Nominating and Corporate Governance Committee |
| Replacement Info | Not disclosed |
| Background Details | President & CEO and director of Century Therapeutics since Dec 2023; chairman since Aug 2025; prior COO of Neogene Therapeutics (May 2021–Dec 2023); prior senior roles at Bristol-Myers Squibb; MBA (Wharton) and Pharm.D. (Duquesne) |
| Board/Committee Role Changes | Not disclosed |
Original SEC Filing: Corbus Pharmaceuticals Holdings, Inc. [ CRBP ] - 8-K - May. 14, 2026
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.